DUBLIN--(BUSINESS WIRE)-- Research and Markets (http://www.researchandmarkets.com/research/f48fd7/boehringer_ingelhe) has announced the addition of the "Boehringer Ingelheim GmbH: PharmaVitae Profile" company profile to their offering.
This analysis examines the historical and forecast performance for Boehringer Ingelheim in the Rx pharmaceutical sector. The profile encompasses company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.
Key reasons to purchase this title
- Benchmark Boehringer Ingelheim's performance against key rivals in the prescription pharmaceutical sector
- Evaluate the impact of upcoming patent expiries for Flomax and Sifrol on the company's outlook
- Track the progress of key new launches including Pradaxa and Ondero, upon which the company is highly reliant
Key Topics Covered:
Chapter 1 About this profile
Chapter structure
Chapter 2 Executive summary
Chapter 3 Quarterly news update
Chapter 4 Company introduction
Chapter 5 Company sales
Chapter 6 Company financials
Chapter 7 Key products and competitors
Chapter 8 Appendix
Companies Mentioned:
- Abbott Laboratories
- Astellas Pharma
- AstraZeneca PLC
- Boehringer Ingelheim GmbH
- Daiichi Sankyo, Ltd.
- Eli Lilly and Company
- GlaxoSmithKline Plc
- IMS Health
- Johnson & Johnson
- Merck & Co., Inc.
- Novartis AG
- Pfizer Inc
For more information visit http://www.researchandmarkets.com/research/f48fd7/boehringer_ingelhe
Source: Datamonitor
CONTACT:
Research and Markets
Laura Wood, Senior Manager,
[email protected]
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
KEYWORDS: Europe Germany
INDUSTRY KEYWORDS: Health Pharmaceutical
MEDIA:
| Logo |